<ul><li>Staying Well </li></ul><ul><li>Your Energy Levels </li></ul><ul><li>How Well You Can Think </li></ul><ul><li>How Fast You Age </li></ul>The Importance of the Immune System to: The greatest breakthrough in the science of immunology transfer factors/nanofactors
The Immune System 1. Immune system is involved in fighting viruses, bacteria, fungi, parasites, mutated cells that could turn into cancer cells. 2. The immune system is involved in detoxifying trillions of cells in your body. Each cell produces toxins. 3. The immune system is fighting free radicals or oxidation that ages you faster and leads to disease. 4. A dysfunctional immune system can lead to heart disease, diabetes, Alzheimer’s, arthritis, and other autoimmune and inflammatory conditions. 5. The immune system is involved in the cellular renewal and repair process.
The immune system has master regulators that initiate actions of other components of the immune system. Transfer factors are master regulators of the immune system. NK Cells, T Cells, B Cells, White Blood Cells, TNF alpha, Interferon, Interleukins, Lymphocytes, etc…
<ul><li>Graduated from New York University’s School of Medicine in 1943. </li></ul><ul><li>Head of Infectious Diseases and Immunology at N.Y.U. in 1959. </li></ul><ul><li>Director of N.Y.U.'s Cancer Center from 1974 to 1979. </li></ul><ul><li>Director of N.Y.U.'s AIDS Research Center from 1989 to 1994. </li></ul><ul><li>Founding editor of the Journal of Cellular Immunology. </li></ul><ul><li>Member of the National Academy of Sciences. </li></ul>Dr. H. Sherwood Lawrence Career Dr. H. Sherwood Lawrence
The history of transfer factors Dr. H. Sherwood Lawrence <ul><li>Dr. H. Sherwood Lawrence made an amazing discovery in 1949 when studying tuberculosis. </li></ul><ul><li>Dr. Lawrence was trying to determine if any component of the blood could convey tuberculin sensitivity from an exposed recovered tuberculosis donor to a newly infected patient. </li></ul><ul><li>What he found was that a fraction of small molecules was able to transfer tuberculin sensitivity to a naive recipient by injecting an extract of white blood cells (leukocytes) from a previously infected, now healthy subject, into a newly infected patient. </li></ul><ul><li>He found that this extract contained a factor capable of transferring immunity. </li></ul>Dr. Lawrence named this substance “ transfer factors .” Another name for transfer factors is dialyzable leukocytes .
The early studies on transfer factors were based on blood derived transfer factors. Research breaks out all over the world!
Early studies with blood derived transfer factors Birth Defects Orig Artic Ser 1975;11(1):449-56 Transfer factor II: results of therapy. ( Several Diseases listed below ) Spitler LE, Levin AS, Fudenberg HH. Transfer factor is a dialyzable extract of sensitized leukocytes, which transfers reactivity from skin test-positive donors to skin test-negative recipients. Transfer factor supplied by our laboratory has been used therapeutically to induce cellular immunity in 78 patients around the world. Many patients received multiple doses of transfer factor ranging from 1 unit given every 6 months for 3 years to 1 unit every week for 6 months to as much as 8 units per week for a brief period. A total of 299 units of transfer factor have been given. Diseases in which transfer factor appeared to cause improvement include the Wiskott-Aldrich syndrome , severe combined immunodeficiency disease , mucocutaneous candidiasis , chronic active hepatitis , coccidioidmycosis , dysgammaglobulinemia , Behcet disease , aphthous stomatitis , linear morphea , familial keratoacanthoma and malignancy .
Early studies with blood derived transfer factors Med Cutan Ibero Lat Am 1977;5(5):361-6 [Therapy with transfer factor in a case of recidivating herpes with polymorphous erythema]. [Article in Spanish] Garcia-Calderon PA, Alomar A, Garcia-Calderon JV, Vich JM, De Moragas JM. A young woman had recidivating herpes with erythema multiforme for several years. When conventional therapy failed to correct this condition she was treated with Transfer Factor (TF). Immunologic anomalies which had been registered previously became normal after the first application of TF. The skin lesions disappeared after the fourth dose. Six months later a new skin manifestation with immunologic alterations became apparent. They disappeared after two doses of TF. A year and a half later the patient has no lesions and the immunologic parameters, which were monitored throughout this period, are normal.
Early studies with blood derived transfer factors Med Pediatr Oncol 1979;6(4):295-301 A study of transfer factor for opportunistic infections in cancer patients . Ketchel SJ, Rodriguez V, Stone A, Gutterman JU. Although supportive care during therapy of patients with malignancies has improved, infection remains the major cause of death in these patients. The problem of "opportunistic" infections is becoming more apparent as better antibiotics are found. The control of these infections depends in part on mechanisms of cell-mediated immunity. It has been demonstrated that delayed-type hypersensitivity can be transferred from one person to another. Therefore, we used transfer factor in the treatment of 15 patients, most with leukemia, who had fungal, viral, or mycobacterial infections that were not responding to conventional therapy. Seven of ten evaluable patients had therapeutic control of their infections while receiving transfer factor. Transfer factor appears to have contributed to these clinical improvements and is a modality of treatment that deserves further investigation.
Early studies with blood derived transfer factors Dermatologica 1981;163(2):177-85 Transfer factor in the treatment of herpes simplex types 1 and 2 . Khan A, Hansen B, Hill NO, Loeb E, Pardue AS, Hill JM. Transfer factor potentiates cellular immunity and induces interferon. It was because of these properties that transfer factor was tried in 17 patients with recurrent herpes simplex types 1 and 2. Transfer factor was administered in doses ranging from 5 to 10 U/m2 i. m. The interval between injections varied from 1 week to 3 months. 16 patients could be evaluated clinically in whom the recurrence rate decreased from 10.7 +/- 6.1 to 2.1 +/- 2.5 (mean SD). The reduction was statistically significant. 8 patients were completely free of disease while the other 8 had reduced number of episodes during the period of observation, 7 patients had abnormal T cell function as reflected by the low number of T cells or low lymphocyte transformation. Statistically significant improvement in the T cell function was observed. Delayed hypersensitivity skin test reactions also improved significantly.
Early studies with blood derived transfer factors J Neurol. 1983;230(2):73-80. Immunological treatment of multiple sclerosis . Hughes RA. Immunosuppressive treatment of multiple sclerosis (MS) is based on the autoimmune hypothesis for which the main evidence is the close histological similarity between the human disease and chronic relapsing EAE. Although controlled trials indicate that ACTH is effective in accelerating recovery from relapses, long term ACTH or oral steroids are ineffective. Two controlled trials have suggested a beneficial effect of azathioprine, but neither was conducted "blind" and neither was sufficiently convincing to cause the widespread adoption of azathioprine by neurologists. One controlled trial, also not blind, reported a beneficial effect of an intensive course of cyclophosphamide, but this hazardous treatment will not be widely adopted unless other trials confirm this result. The converse hypothesis that MS is due to a deficient immune response to a virus has led to trials of immunostimulation. Interferon and levamisole have proven ineffective so far, but transfer factor slowed disease progression in one well conducted trial. PMID: 6196462 [PubMed - indexed for MEDLINE]
Dialyzable leukocyte extract (transfer factor) in the treatment of superinfected fistulating tuberculosis of the bone . Cell Immunol 1984 Mar;84(1):200-5 (ISSN: 0008-8749) Zielinski CC; Savoini E; Ciotti M; Orani R; Konigswieser H; Eibl MM The effect of the addition of dialyzable leukocyte extract (DLE)(transfer factor) to tuberculostatic drugs in the treatment of superinfected fistulating tuberculosis of bones and joints was evaluated in a controlled study. Eleven patients whose disease had persisted for a mean of 20 +/- 4.8 years and had proved to be resistant to antibiotics and tuberculostatic drugs were treated with an additional combined tuberculostatic drug regimen consisting of isoniazide, ethambutol, and rifampin for a control period of 2 years; after this therapy had failed as judged by the persistence of the superinfected fistulae and of the symptoms, DLE was added to the regimen. The result of this therapeutic approach was evaluated after another 2 years. Through this therapy, a closure of the fistulae was achieved in 9 out of the 11 patients (P less than 0.001) with a concomitant decrease of symptoms. DLE may prove beneficial in the treatment of patients with superinfected fistulating tuberculous osteomyelitis. Early studies with blood derived transfer factors
Early studies with blood derived transfer factors Cutis 1984 Sep;34(3):278-81 Treatment of varicella-zoster pneumonia with transfer factor. Winkelmann RK, DeRemee RA, Ritts RE Jr. A 29-year-old woman with a long history of immunoreactive disease--thrombocytopenic purpura, bullous pemphigoid, nephropathy, and hemolytic anemia--contracted generalized herpes zoster and varicella pneumonia. Respiratory failure requiring assisted respiration accompanied progressive chest findings. She recovered rapidly simultaneous with the administration of transfer factor from a healing herpes zoster patient. We believe that this therapy should be attempted in similar desperate circumstances.
Early studies with blood derived transfer factors Proc Soc Exp Biol Med 1985 Mar;178(3):468-75 Transfer factor for the treatment of HBsAg-positive chronic active hepatitis . Roda E, Viza D, Pizza G, Mastroroberto L, Phillips J, De Vinci C, Barbara L. Transfer factor was obtained from four patients having recovered from acute type-B viral hepatitis. It was replicated in vitro using the LDV/7 lymphoblastoid cell line. This in vitro-produced transfer factor specific for hepatitis B (TFdL-H) was administered to 10 randomly selected patients with biochemically and histologically proven HBsAg-positive chronic active hepatitis (CAH) at 15-day intervals over a 6-month period. In three out of four initially HBeAg-positive patients, anti-HBe antibodies appeared when the HBeAg disappeared. In one of these patients and in two other HBsAg-positive patients, the appearance of anti-HBs antibodies was noted. The improvement in several biochemical parameters of the TFdL-H patients was statistically significant when compared with those of another group of 10 randomly selected untreated CAH patients. Liver biopsies in six out of eight treated patients showed a histological improvement at the end of the treatment. These results suggest that TFdL-H may be used with beneficial.
Early studies with blood derived transfer factors Med Interne 1985 Apr-Jun;23(2):135-40 Effect of long-term therapy with transfer factor in rheumatoid arthritis . Georgescu C. Specific immunotherapy with transfer factor (TF) was used in a chronic experiment in a group of 50 female patients with rheumatoid arthritis (RA) stage I-III. The patients were followed up for 24 months, clinical and biologic examinations being repeated every 3 months. In this period the patients received beside the basic nonsteroid anti-inflammatory therapy, one unit TF every week over a period of 6 months then one until TF every month (10 patients) to the end of experiment. Of the 50 patients 15 (30%) did not respond to the therapy and the experiments had to be interrupted after 6 months. Excellent, very good and good results were obtained in 35 patients (70%). In 12 patients the response was good but the dose of TF had to be increased to two units/week in the first 6 months. In 13 patients the results obtained were very good and therapy with nonsteroid products + TF was continued even after the first 6 months. In 10 patients with RA stage I the results obtained were excellent and after 6 months the nonsteroid therapy could be interrupted and the therapy was continued only with one unit TF every month. The study confirmed the fact that specific immunotherapy with TF represents an important adjuvant in the treatment of rheumatoid arthritis (RA).
Transfer factors from blood are not capable of being made commercially available for the masses to take advantage of this discovery. Because of the dangers surrounding contamination to blood, blood transfer factors are not an option anymore. With the advent of AIDS and hepatitis C contaminating blood supplies, the hope for blood derived transfer factors being made commercially for the public was no longer an option. In addition, a great number of antibiotics also became popular and inexpensive so research slowed down.
A Breakthrough! Transfer factors were discovered in mothers’ breast milk. Scientists then began to study whether other mammals also contained transfer factors in their colostrum. Not only are animals able to endure more harsh and hostile threats from unfiltered environments, it was also found that mother cows actually produce 8x more colostum than what the calf can drink, thus solving the available source dilemma. This was soon noticed in cows. When newborn cows did not or could not nurse, they quickly died. Infection, not starvation, was the usual cause of death. Researchers realized that the mother was passing immunity information to the calf after birth, and the only means for this transfer was her first milk. Due to obvious reasons, obtaining colostrum from human donors was not feasible. While searching for alternative sources of colostrum, researchers discovered that transfer factors were present in the first milk of other milk producing mammals. In addition, the transfer factors found in other mammals were non-species specific and the transfer factors found were better .
Studies using bovine colostrum based transfer factors Anticancer Res 1990 Sep-Oct;10(5A):1183-7 Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma . Neequaye J, Viza D, Pizza G, Levine PH, De Vinci C, Ablashi DV, Biggar RJ, Nkrumah FK. University of Ghana School of Medicine, Accra. Twenty-seven children with abdominal Burkitt's lymphoma (stage III), who had achieved complete remission, were entered into a prospective controlled trial of adjunct treatment with Epstein-Barr virus (EBV)-specific transfer factor (TF). Two patients treated with TF and 2 controls relapsed early (less than or equal to 12 weeks). Two out of 12 TF-treated patients and 5 out of 11 controls subsequently suffered relapses. Time to first late relapse was longer among TF-treated patients (p = 0.08), and no late relapse occurred while a patient was receiving TF treatment. Thus it seems that specific TF might be useful in the management of endemic Burkitt's lymphoma and also in the treatment of other virus-associated cancers and diseases. Publication Types: Clinical trial Controlled clinical trial
Studies using bovine colostrum based transfer factors Biotherapy 1996;9(1-3):41-7 Preliminary observations using HIV -specific transfer factor in AIDS . Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH, De Vinci C, Viza D. Immunodiagnosis and Immunotherapy Unit, Ospedale S. Orsola-Malpighi, Bologna, Italy. Twenty five HIV-1-infected patients, at various stages (CDC II, III and IV) were treated orally with HIV-1-specific transfer factor (TF) for periods varying from 60 to 1870 days. All patients were receiving antiviral treatments in association with TF. The number of lymphocytes, CD4 and CD8 subsets were followed and showed no statistically significant variations. In 11/25 patients the number of lymphocytes increased, whilst in 11/25 decreased; similarly an increase of the CD4 lymphocytes was observed in 11/25 patients and of the CD8 lymphocytes in 15/25. Clinical improvement or a stabilized clinical condition was noticed in 20/25 patients, whilst a deterioration was seen in 5/25. In 12/14 anergic patients, daily TF administration restored delayed type hypersensitivity to recall antigens within 60 days. These preliminary observations suggest that oral HIV-specific TF administration, in association with antiviral drugs, is well tolerated and seems beneficial to AIDS patients, thus warranting further investigation. Publication Types: Clinical trial, phase I
Studies using bovine colostrum based transfer factors Biotherapy 1996;9(1-3):133-8 Use of transfer factor for the treatment of recurrent non-bacterial female cystitis ( NBRC ): a preliminary report. De Vinci C, Pizza G, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V, Viza D. Immunodiagnosis and Immunotherapy Unit, 1st-Division of Urology, Bologna, Italy. Results of conventional treatment of female non-bacterial recurrent cystitis (NBRC) are discouraging. Most patients show an unexpected high incidence of vaginal candidiasis, while their cell mediated immunity to Herpes simplex viruses (HSV) and Candida antigens seems impaired, and it is known that the persistence of mucocutaneous chronic candidiasis is mainly due to a selective defect of CMI to Candida antigens. Twenty nine women suffering of NBRC, and in whom previous treatment with antibiotics and non-steroid anti-inflammatory drugs was unsuccessful, underwent oral transfer factor (TF) therapy. TF specific to Candida and/or to HSV was administered bi-weekly for the first 2 weeks, and then once a week for the following 6 months. No side effects were observed during treatment. The total observation period of our cohort was 24379 days with 353 episodes of cystitis recorded and a cumulative relapse index (RI) of 43. The observation period during and after treatment was 13920 days with 108 relapses and a cumulative RI of 23 (P < 0.0001). It, thus, seems that specific TF may be capable of controlling NBRC and alleviate the symptoms. Publication Types: Clinical trial
Technology advances to a point where this product can be made available to the public. Research company secures patents and sets up its own scientific team to continue exploring the many benefits of transfer factors.
Since the discovery of transfer factors in 1949: <ul><li>Over $40 million (USD) has been invested in research. </li></ul><ul><li>Scientists from over 60 different nations were involved with this research. </li></ul><ul><li>More than 3,000 medical studies have been published, documenting the benefits of transfer factors. </li></ul>Transfer factors are featured in the PDR® for Nonprescription Drugs, Dietary Supplements, and Herbs. The PDR is used by most hospitals and clinics in the U.S.
The Russian Government Endorses Transfer factors <ul><li>The Effectiveness of TF Use in Viral Hepatitis </li></ul><ul><li>The Use of TF in Chlamydia Infections </li></ul><ul><li>The Effectiveness of TF Use in Osteomyelitis </li></ul><ul><li>The Use of TF in Immunorehabilitation Therapy of HIV Infection </li></ul><ul><li>The Use of TF in the Complex Treatment of Atopic Conditions </li></ul><ul><li>Immunomodulating Effect of TF Use in Opisthorchiasis </li></ul><ul><li>The Role of TF in Immunorehabilitation of Oncology Patients </li></ul><ul><li>Gastric Cancer after Surgery </li></ul><ul><li>The Effectiveness of TF PLUS in the Complex Treatment of Duodenal Ulcer </li></ul><ul><li>In case of immunodeficiency persistence after a 2 month treatment </li></ul>Continued Breakthroughs by Scientists …
Transfer factors effects on other nutrients Transfer factors increase the activity and benefits of any nutrient that you are consuming. Transfer factors, in their regulatory role in the body, are involved in the functions of the various molecules, cells, and body chemicals that nutrients are affecting. Transfer factors synergize with these nutrients to enhance their effect on the body. In the Russian studies that discovered transfer factors’ role in decreasing oxidation in the human body, it was found that the effectiveness of vitamin C was increased by 80%. The body doesn’t produce vitamin C, so how did transfer factors increase its activity by 80%? This is an example of transfer factors’ influence on all other nutrients in your body. Graph 1 shows that the active ascorbates (reduced form), the form capable of neutralizing free radicals, was differentially increased 80% in the Transfer Factor Test Group versus 12.4% in the Control Group.
Transfer Factors Tri-Factor formula increases NK cell activity by over 500% more than any other known nutrient. Scientists in Japan recently conducted a major study of individuals who had low natural killer cell activity. Those who were low in NK cell activity developed cancer at a greater rate than individuals with a higher level of NK cell activity. The immune system makes all the difference! Transfer factors compared to the top 196 nutrients
The data in Graph 4 clearly shows that there has been an increase in undamaged proteins. In other words, protein peroxidation was decreased. Interestingly, in Alzheimer’s damaged brain tissue, there is a highly elevated amount of antioxidant enzymes (proteins) that are inactive because they themselves have been oxidized and functionally destroyed even as they were being formed. Transfer factors are found to regulate antioxidants
Graph 2 represents the glutathione levels. Again we see a rise in the amount of reduced (active) glutathione, which indicates less oxidative stress. Glutathione is an expensive antioxidant that a number of companies are now touting. There are significant problems associated with the oral delivery of glutathione due to digestive breakdown and recently enterically coated (digestively protected) forms have been introduced into the market. The primary role of glutathione is as an antioxidant. The role of glutathione as a toxin carrier is a secondary but also critical role. The increase in the reduced form of glutathione in the presence of higher amounts of reduced ascorbates frees the glutathione from its antioxidant function and allows it to be used as a toxin carrier, thus helping rid the body of its toxin burden . All enzymes are proteins. Transfer factors are found to regulate antioxidants
Transfer factors increase the body’s natural production of the glutathione S-transferase, which improves cellular detoxification in the human body, by 150%. Most nutritional supplements only help the detoxification process in the liver, but transfer factors have an effect on all the trillions of cells in your body. Transfer factors are found to regulate antioxidants
There are two ways to visualize the shifts in erythrocyte (red blood cell) stability. One is to plot the two curves and show the shift toward more stable cells. (See Graphs 6-7). The other way is to assign a relative value of each stability class and then calculate a cumulative weighted cell stability value. I chose zero as the stability value of those cells that were ruptured before the experiment started. I then assigned 1 through 4 to the value of the succeeding stability classes. Graph 8 shows the calculated values. Again we see the protective effects of transfer factor reflected in the increased cumulative cell stability rating in the transfer factor test group as compared to the control group, which showed a decreased cell stability even four weeks after surgery. Transfer factors are found to regulate antioxidants
Transfer Factors & Inflammation Lipid oxidation indicates the damage done to essential fatty acids and cholesterol. Oxidized cholesterol is an irritant to the blood vessels and triggers a number of inflammatory immune system responses. The transfer factor test group showed a >35% decrease in oxidative damage to the blood lipids. Unlike COX-2 inhibitors, such as Vioxx, which create heart disease, transfer factors help the immune system regulate a great number of cells that cause inflammation.
Discovery of Nanofactors Filters Nanofactor Transfer factor
Nanofactors Creating immune balance Transfer factors and nanofactors work as a team . Transfer factors provide the intelligence while nanofactors provide the modulating and regulating dimension. Nanofactors provide the feedback mechanism.
Breakthrough in the science of anti-aging INTERNATIONALER MEDIZINISCHER KONGRESS HANNOVER CONGRESS CENTRUM Programm Abstracts ON THE POSSIBILITY OF REDUCING BIOLOGICAL AGE USING TRANSFER FACTOR Russian University of People’s Friendship, Moscow, Russia National Gerontolgical Centre, Laboratory for Gerontology MGSU, Moscow, Russia A.Ya. Chizhov, V.А. Santalova, V.N. Krut’ko, V.I.Dontsov Immunological reactivity of people living in big cities is characterized by high occurrence of ecologically induced secondary immunodeficits. Irreversible changes in the immune system lead to exhaustion of reserves and development of a pathology. The close interaction is known between decline in functional activity of the immune system and the process of aging. Therefore it seems feasible to explore the influence of perspective immunomodulators on the parameters of the biological age. There is a close link between the decrease of functional activity of the immune system and aging. Thus, we decided to study immunomodulators to determine to what extent they may affect biological age indices. A new immune theory of aging (V.I.Dontsov, V.N. Krut’ko, 2002) points to the role of specific T-lymphocytes subpopulations in sustaining a certain level of normal cellular growth in the body and dwells on the importance of their functional decrease having a strong impact on aging. Stimulation of the function of these cells by Transfer Factor (TF), an immunomodulator produced by 4Life, USA, seemed a plausible method of “treating aging”. The evaluation of the role TF in the process of aging is at the basis of this study. Twelve (12) men aged 55-73 were included in the study. A dose of 300 mg. of the TF product was given daily with meals 5 times a week for 6 weeks. Biological age was determined using the “АPK” method (“Diagnostics of aging: biological age” (National gerontology center, Moscow)). The following biomarkers were used for making the determinations: AP (arterial pressure), pulse wave velocity, VC (vital pulmonary capacity), static balance, Shtange’s test, adaptation testing, body mass, left hand strength, Shulte’s test, Veksler’s test, neuromuscular test, hearing frequency threshold and the SAN’s questionnaire. The functional activities of body systems were evaluated by means of Nakatani’s electropuncture diagnostics. Chronological age of the group was 63.5±0.7. Before the use of TF the biological age of the group differed from chronological by -4.2 ±0.6 years. The majority of men demonstrated a decrease in the functional activity of endocrine and of immune systems’ as well as hyperfunction of the liver and of urinary bladder and hypofunction pancreatic. Results: The study showed that initially disturbed body system functions were significantly normalized. After the course of TF treatment the difference between biological and chronological age was (-8.2) ±0.5 years (p<0.05), which is a rejuvenation effect of 4 years . The above information is an abstract (short overview) on a scientific study of the effect of transfer factors on the aging process. We cannot release the whole study because it is being peer reviewed for publishing in a prestigious medical journal.
Not a vitamin, mineral, herb, fatty acid, or anything like any other nutrient. A complete new category of nutrition. How are transfer factors made?
Comparison of Immune Response with and without Nanofactor <ul><li>TF Plus Advanced </li></ul><ul><li>TF Plus Tri-Factor </li></ul><ul><li>Best Combination </li></ul>Nano TF Plus Adv TF Plus Tri-Factor TF Plus Adv
Transfer factors are the greatest discovery for natural health in the last two centuries. We can make a major difference in India! Our staff provides a service of answering questions. We have a committee of doctors and researchers exploring all of the ways that transfer factors can take one’s health to the optimal level of well-being!